Loading clinical trials...

Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis | Clinical Trials | Clareo Health

UNKNOWNNA

Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis

Efficacy of Exvivo Expanded Autologous Mesenchymal Stem Cell Transplantation Via Peripheral Vein in Patients With Liver Cirrhosis

NCT01499459•Saglik Bilimleri Universitesi Gulhane Tip Fakultesi

View on ClinicalTrials.gov

Summary

This study is aiming to investigate the efficacy of autologous mesenchymal stem cell (MSC) transplantation in 25 randomized patients with liver cirrhosis autologous mesenchymal stem cell will be derived from patients' bone marrows and will be infused via peripheral vein. Liver biopsies will be performed in every patient in the beginning and at 6th month.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•radiological, clinical and histopathological diagnosis of liver cirrhosis
•absence of hepatocellular carcinoma or any malignancies
•no psychiatric disorder
•no serous cardiovascular and pulmonary comorbidities
•serum total bilirubin levels less than 5 mg/dL
•platelet counts more than 30.000 mm3
•more than one year follow up period after initiation of antiviral drugs

Exclusion Criteria

•alcohol intake in last one year
•initiation of antiviral medication in last one year
•systemic diseases

Locations (1)

Gulhane Military Medical Academy Department of Gastroenterology

Ankara, Turkey (Türkiye)

Key Dates

Start Date

June 1, 2008

Primary Completion Date

July 1, 2012

Completion Date

August 1, 2012

Last Updated

March 22, 2012

Enrollment

ESTIMATED participants

Conditions

Liver Cirrhosis

Interventions

autologous mesenchymal stem cell transplantation

GENETIC

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation

NCT06169592

Liver CirrhosisLiver Transplant; Complications

View study

RECRUITING

Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure

NCT07275554

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 22, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis

Inclusion Criteria

Exclusion Criteria

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation

Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure

Validation of New Prognostic Biomarkers in Patients With Decompensated Cirrhosis

Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial

DOAC in Patients with Child a or B Liver Cirrhosis

Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients with Refractory Ascites Candidate to Transjugular Intrahepatic Portosystemic Shunt Placement and Identification of Prognostic Factors Related to Clinical Outcome